Abstract
Background: Brain volumes in regions such as the hippocampus and amygdala have been associated with risk for the development of posttraumatic stress disorder (PTSD). The objective of this study was to determine whether a set of regional brain volumes, measured by magnetic resonance imaging at 2 weeks following mild traumatic brain injury, were predictive of PTSD at 3 and 6 months after injury. Methods: Using data from TRACK-TBI (Transforming Research and Clinical Knowledge in TBI), we included patients (N = 421) with Glasgow Coma Scale scores 13–15 assessed after evaluation in the emergency department and at 2 weeks, 3 months, and 6 months after injury. Probable PTSD diagnosis (PTSD Checklist for DSM-5 score, ≥33) was the outcome. FreeSurfer 6.0 was used to perform volumetric analysis of three-dimensional T1-weighted magnetic resonance images at 3T obtained 2 weeks post injury. Brain regions selected a priori for volumetric analyses were insula, hippocampus, amygdala, superior frontal cortex, rostral and caudal anterior cingulate, and lateral and medial orbitofrontal cortices. Results: Overall, 77 (18.3%) and 70 (16.6%) patients had probable PTSD at 3 and 6 months. A composite volume derived as the first principal component incorporating 73.8% of the variance in insula, superior frontal cortex, and rostral and caudal cingulate contributed to the prediction of 3-month (but not 6-month) PTSD in multivariable models incorporating other established risk factors. Conclusions: Results, while needing replication, provide support for a brain reserve hypothesis of PTSD and proof of principle for how prediction of at-risk individuals might be accomplished to enhance prognostic accuracy and enrich clinical prevention trials for individuals at the highest risk of PTSD following mild traumatic brain injury.
Original language | English (US) |
---|---|
Pages (from-to) | 352-359 |
Number of pages | 8 |
Journal | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging |
Volume | 6 |
Issue number | 3 |
DOIs | |
State | Published - Mar 2021 |
Keywords
- Amygdala
- Brain
- Cingulate
- Insula
- PTSD
- Posttraumatic stress disorder
- TBI
- Traumatic brain injury
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cognitive Neuroscience
- Clinical Neurology
- Biological Psychiatry
Fingerprint
Dive into the research topics of 'Smaller Regional Brain Volumes Predict Posttraumatic Stress Disorder at 3 Months After Mild Traumatic Brain Injury'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, Vol. 6, No. 3, 03.2021, p. 352-359.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Smaller Regional Brain Volumes Predict Posttraumatic Stress Disorder at 3 Months After Mild Traumatic Brain Injury
AU - TRACK-TBI Investigators
AU - Stein, Murray B.
AU - Yuh, Esther
AU - Jain, Sonia
AU - Okonkwo, David O.
AU - Mac Donald, Christine L.
AU - Levin, Harvey
AU - Giacino, Joseph T.
AU - Dikmen, Sureyya
AU - Vassar, Mary J.
AU - Diaz-Arrastia, Ramon
AU - Robertson, Claudia S.
AU - Nelson, Lindsay D.
AU - McCrea, Michael
AU - Sun, Xiaoying
AU - Temkin, Nancy
AU - Taylor, Sabrina R.
AU - Markowitz, Amy J.
AU - Manley, Geoffrey T.
AU - Mukherjee, Pratik
AU - Adeoye, Opeolu
AU - Badjatia, Neeraj
AU - Boase, Kim
AU - Barber, Jason
AU - Bodien, Yelena
AU - Bullock, M. Ross
AU - Chesnut, Randall
AU - Corrigan, John D.
AU - Crawford, Karen
AU - Duhaime, Ann Christine
AU - Ellenbogen, Richard
AU - Feeser, V. Ramana
AU - Ferguson, Adam R.
AU - Foreman, Brandon
AU - Gardner, Raquel
AU - Gaudette, Etienne
AU - Goldman, Dana
AU - Gonzalez, Luis
AU - Gopinath, Shankar
AU - Gullapalli, Rao
AU - Hemphill, J. Claude
AU - Hotz, Gillian
AU - Keene, C. Dirk
AU - Korley, Frederick K.
AU - Kramer, Joel
AU - Kreitzer, Natalie
AU - Lindsell, Chris
AU - Machamer, Joan
AU - Madden, Christopher
AU - Martin, Alastair
AU - Valadka, Alex
N1 - Funding Information: This research was supported by the National Institutes of Health (Grant No. U01NS086090 [to GTM] ) and U.S. Department of Defense (Grant No. W81XWH-14-2-0176 [to GTM] ). Abbott Laboratories provided funding for add-in TRACK-TBI clinical studies. One Mind provided funding for TRACK-TBI patients’ stipends and support to clinical sites. Funding Information: This research was supported by the National Institutes of Health (Grant No. U01NS086090 [to GTM]) and U.S. Department of Defense (Grant No. W81XWH-14-2-0176 [to GTM]). Abbott Laboratories provided funding for add-in TRACK-TBI clinical studies. One Mind provided funding for TRACK-TBI patients? stipends and support to clinical sites. The TRACK-TBI Investigators: Opeolu Adeoye, M.D. University of Cincinnati; Neeraj Badjatia, M.D. University of Maryland; Kim Boase, University of Washington; Jason Barber, M.S. University of Washington; Yelena Bodien, Ph.D. Massachusetts General Hospital; M. Ross Bullock, M.D. Ph.D. University of Miami; Randall Chesnut, M.D. University of Washington; John D. Corrigan, Ph.D. American Board of Professional Psychology, Ohio State University; Karen Crawford, University of Southern California; Ann-Christine Duhaime, M.D. MassGeneral Hospital for Children; Richard Ellenbogen, M.D. University of Washington; V. Ramana Feeser, M.D. Virginia Commonwealth University; Adam R. Ferguson, Ph.D. University of California San Francisco; Brandon Foreman, M.D. University of Cincinnati; Raquel Gardner, University of California San Francisco; Etienne Gaudette, Ph.D. University of Southern California; Dana Goldman, Ph.D. University of Southern California; Luis Gonzalez, TIRR Memorial Hermann; Shankar Gopinath, M.D. Baylor College of Medicine; Rao Gullapalli, Ph.D. University of Maryland; J. Claude Hemphill, M.D. University of California San Francisco; Gillian Hotz, Ph.D. University of Miami; Sonia Jain, Ph.D. University of California San Diego; C. Dirk Keene, M.D. Ph.D. University of Washington; Frederick K. Korley, M.D. Ph.D. University of Michigan; Joel Kramer, Psy.D. University of California San Francisco; Natalie Kreitzer, M.D. University of Cincinnati; Chris Lindsell, Ph.D. Vanderbilt University; Joan Machamer, M.A. University of Washington; Christopher Madden, M.D. UT Southwestern; Alastair Martin, Ph.D. University of California San Francisco; Thomas McAllister, M.D. Indiana University; Randall Merchant, Ph.D. Virginia Commonwealth University; Laura B. Ngwenya, M.D. Ph.D. University of Cincinnati; Florence Noel, Ph.D. Baylor College of Medicine; Amber Nolan, M.D. Ph.D. University of California San Francisco; Eva Palacios, Ph.D. University of California San Francisco; Daniel Perl, M.D. Uniformed Services University; Ava Puccio, Ph.D. University of Pittsburgh; Miri Rabinowitz, Ph.D. University of Pittsburgh; Claudia Robertson, M.D. Baylor College of Medicine; Jonathan Rosand, M.D. M.Sc. Massachusetts General Hospital; Angelle Sander, Ph.D. Baylor College of Medicine; Gabriella Satris, University of California San Francisco; David Schnyer, Ph.D. UT Austin; Seth Seabury, Ph.D. University of Southern California; Arthur Toga, Ph.D. University of Southern California; Alex Valadka, M.D. Virginia Commonwealth University; Paul Vespa, M.D. University of California, Los Angeles; Kevin Wang, Ph.D. University of Florida; John K. Yue, M.D. University of California San Francisco; Ross Zafonte, Harvard Medical School. We thank Alison M. Sweet, University of California San Diego, for providing additional editorial assistance. EY had a patent pending for USPTO No. 62/269,778. GTM received grants from the National Institute of Neurological Disorders and Stroke during the conduct of the study and research funding from the U.S. Department of Energy, grants from the Department of Defense, research funding from Abbott Laboratories, grants from the National Football League Scientific Advisory Board, and research funding from One Mind outside the submitted work. In addition, GTM had a patent issued for Interpretation and Quantification of Emergency Features on Head Computed Tomography. He served for 2 seasons as an unaffiliated neurologic consultant for home games of the Oakland Raiders; he was compensated $1500 per game for 6 games during the 2017 season but received no compensation for this work during the 2018 season. MBS received personal fees from Acadia Pharmaceuticals, Amgen, Aptinyx, Bionomics, GW Pharma, and Janssen and personal fees and stock options from Oxeia Biopharmaceuticals outside the submitted work. RD-A received personal fees and research funding from Neural Analytics Inc. and travel reimbursement from Brain Box Solutions Inc. outside the submitted work. Dana Goldman received personal fees from Amgen, Avanir Pharmaceuticals, Acadia Pharmaceuticals, Aspen Health Strategy Group, and Celgene outside the submitted work. Natalie Kreitzer received personal fees from Portola outside the submitted work. PM received grants from GE Healthcare and nonfinancial support from GE-NFL Head Health Initiative outside the submitted work. In addition, PM had a patent pending for USPTO No. 62/269,778. Jonathan Rosand received personal fees from Boehringer Ingelheim and New Beta Innovations outside the submitted work. Ross Zafonte received royalties from Oakstone for an educational CD (Physical Medicine and Rehabilitation: a Comprehensive Review) and Demos publishing for serving as coeditor of Brain Injury Medicine. Ross Zafonte serves or served on the scientific advisory boards of Myomo, Oxeia Biopharma, BioDirection, and ElMindA. He also evaluates patients in the MGH Brain and Body-TRUST Program, which is funded by the National Football League Players Association. Ross Zafonte served on the Mackey White Committee. All other authors report no biomedical financial interests or potential conflicts of interest. Funding Information: EY had a patent pending for USPTO No. 62/269,778. GTM received grants from the National Institute of Neurological Disorders and Stroke during the conduct of the study and research funding from the U.S. Department of Energy, grants from the Department of Defense, research funding from Abbott Laboratories, grants from the National Football League Scientific Advisory Board, and research funding from One Mind outside the submitted work. In addition, GTM had a patent issued for Interpretation and Quantification of Emergency Features on Head Computed Tomography. He served for 2 seasons as an unaffiliated neurologic consultant for home games of the Oakland Raiders; he was compensated $1500 per game for 6 games during the 2017 season but received no compensation for this work during the 2018 season. MBS received personal fees from Acadia Pharmaceuticals, Amgen, Aptinyx, Bionomics, GW Pharma, and Janssen and personal fees and stock options from Oxeia Biopharmaceuticals outside the submitted work. RD-A received personal fees and research funding from Neural Analytics Inc. and travel reimbursement from Brain Box Solutions Inc. outside the submitted work. Dana Goldman received personal fees from Amgen, Avanir Pharmaceuticals, Acadia Pharmaceuticals, Aspen Health Strategy Group, and Celgene outside the submitted work. Natalie Kreitzer received personal fees from Portola outside the submitted work. PM received grants from GE Healthcare and nonfinancial support from GE-NFL Head Health Initiative outside the submitted work. In addition, PM had a patent pending for USPTO No. 62/269,778. Jonathan Rosand received personal fees from Boehringer Ingelheim and New Beta Innovations outside the submitted work. Ross Zafonte received royalties from Oakstone for an educational CD (Physical Medicine and Rehabilitation: a Comprehensive Review) and Demos publishing for serving as coeditor of Brain Injury Medicine. Ross Zafonte serves or served on the scientific advisory boards of Myomo, Oxeia Biopharma, BioDirection, and ElMindA. He also evaluates patients in the MGH Brain and Body-TRUST Program, which is funded by the National Football League Players Association. Ross Zafonte served on the Mackey White Committee. All other authors report no biomedical financial interests or potential conflicts of interest. Publisher Copyright: © 2020
PY - 2021/3
Y1 - 2021/3
N2 - Background: Brain volumes in regions such as the hippocampus and amygdala have been associated with risk for the development of posttraumatic stress disorder (PTSD). The objective of this study was to determine whether a set of regional brain volumes, measured by magnetic resonance imaging at 2 weeks following mild traumatic brain injury, were predictive of PTSD at 3 and 6 months after injury. Methods: Using data from TRACK-TBI (Transforming Research and Clinical Knowledge in TBI), we included patients (N = 421) with Glasgow Coma Scale scores 13–15 assessed after evaluation in the emergency department and at 2 weeks, 3 months, and 6 months after injury. Probable PTSD diagnosis (PTSD Checklist for DSM-5 score, ≥33) was the outcome. FreeSurfer 6.0 was used to perform volumetric analysis of three-dimensional T1-weighted magnetic resonance images at 3T obtained 2 weeks post injury. Brain regions selected a priori for volumetric analyses were insula, hippocampus, amygdala, superior frontal cortex, rostral and caudal anterior cingulate, and lateral and medial orbitofrontal cortices. Results: Overall, 77 (18.3%) and 70 (16.6%) patients had probable PTSD at 3 and 6 months. A composite volume derived as the first principal component incorporating 73.8% of the variance in insula, superior frontal cortex, and rostral and caudal cingulate contributed to the prediction of 3-month (but not 6-month) PTSD in multivariable models incorporating other established risk factors. Conclusions: Results, while needing replication, provide support for a brain reserve hypothesis of PTSD and proof of principle for how prediction of at-risk individuals might be accomplished to enhance prognostic accuracy and enrich clinical prevention trials for individuals at the highest risk of PTSD following mild traumatic brain injury.
AB - Background: Brain volumes in regions such as the hippocampus and amygdala have been associated with risk for the development of posttraumatic stress disorder (PTSD). The objective of this study was to determine whether a set of regional brain volumes, measured by magnetic resonance imaging at 2 weeks following mild traumatic brain injury, were predictive of PTSD at 3 and 6 months after injury. Methods: Using data from TRACK-TBI (Transforming Research and Clinical Knowledge in TBI), we included patients (N = 421) with Glasgow Coma Scale scores 13–15 assessed after evaluation in the emergency department and at 2 weeks, 3 months, and 6 months after injury. Probable PTSD diagnosis (PTSD Checklist for DSM-5 score, ≥33) was the outcome. FreeSurfer 6.0 was used to perform volumetric analysis of three-dimensional T1-weighted magnetic resonance images at 3T obtained 2 weeks post injury. Brain regions selected a priori for volumetric analyses were insula, hippocampus, amygdala, superior frontal cortex, rostral and caudal anterior cingulate, and lateral and medial orbitofrontal cortices. Results: Overall, 77 (18.3%) and 70 (16.6%) patients had probable PTSD at 3 and 6 months. A composite volume derived as the first principal component incorporating 73.8% of the variance in insula, superior frontal cortex, and rostral and caudal cingulate contributed to the prediction of 3-month (but not 6-month) PTSD in multivariable models incorporating other established risk factors. Conclusions: Results, while needing replication, provide support for a brain reserve hypothesis of PTSD and proof of principle for how prediction of at-risk individuals might be accomplished to enhance prognostic accuracy and enrich clinical prevention trials for individuals at the highest risk of PTSD following mild traumatic brain injury.
KW - Amygdala
KW - Brain
KW - Cingulate
KW - Insula
KW - PTSD
KW - Posttraumatic stress disorder
KW - TBI
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=85102725035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102725035&partnerID=8YFLogxK
U2 - 10.1016/j.bpsc.2020.10.008
DO - 10.1016/j.bpsc.2020.10.008
M3 - Article
C2 - 33386283
AN - SCOPUS:85102725035
SN - 2451-9022
VL - 6
SP - 352
EP - 359
JO - Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
JF - Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
IS - 3
ER -